- Corporate Officers - F
- Frates James M
Insider Trading History of Frates James M
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Frates James M since 2015.
This trader's CIK number is 1235598.
At the time of last reporting, Frates James M was the Chief Financial Officer of Amylyx Pharmaceuticals, Inc.. (stock ticker symbol AMLX).
Also see all insider trading activities at Amylyx Pharmaceuticals, Inc..
Note that in the past
FRATES JAMES M also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Sage Therapeutics, Inc. (SAGE) by Frates James M
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | SAGE | 1,810 | $99,734 | 0 | $0 | 0 | $0 |
| 2019 | SAGE | 0 | $0 | 23,500 | $3,593,475 | 23,500 | $365,060 |
| 2018 | SAGE | 0 | $0 | 7,000 | $1,078,000 | 7,000 | $62,440 |
Yearly summary of insider trading at Alkermes Plc. (ALKS) by Frates James M
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | ALKS | 0 | $0 | 0 | $0 | 32,308 | $258,080 |
| 2019 | ALKS | 0 | $0 | 0 | $0 | 33,500 | $234,800 |
| 2018 | ALKS | 0 | $0 | 16,842 | $842,184 | 9,938 | $0 |
| 2017 | ALKS | 0 | $0 | 41,864 | $2,060,859 | 54,301 | $514,508 |
| 2016 | ALKS | 0 | $0 | 48,731 | $2,713,261 | 66,023 | $751,925 |
| 2015 | ALKS | 0 | $0 | 140,000 | $9,198,309 | 158,335 | $1,790,093 |
Yearly summary of insider trading at Amylyx Pharmaceuticals, Inc. (AMLX) by Frates James M
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | AMLX | 0 | $0 | 21,454 | $192,462 | 0 | $0 |
| 2024 | AMLX | 40,000 | $101,359 | 4,508 | $77,906 | 0 | $0 |
| 2023 | AMLX | 0 | $0 | 67,658 | $2,028,153 | 55,665 | $382,975 |
Insider trading activities at 3 companies by Frates James M:
1. Sage Therapeutics, Inc. (SAGE)
2. Alkermes Plc. (ALKS)
3. Amylyx Pharmaceuticals, Inc. (AMLX)
Table 1. Insider trading of Sage Therapeutics, Inc. (SAGE) by Frates James M
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-06-16 | SAGE | Buy | 1,810 | 55.10 | 99,734 |
| 2019-08-15 | SAGE | Option Ex | 8,000 | 28.35 | 226,800 |
| 2019-08-15 | SAGE | Sale | 8,000 | 160.58 | 1,284,640 |
| 2019-05-06 | SAGE | Option Ex | 8,000 | 8.92 | 71,360 |
| 2019-05-06 | SAGE | Sale | 8,000 | 162.22 | 1,297,760 |
| 2019-01-23 | SAGE | Option Ex | 7,500 | 8.92 | 66,900 |
| 2019-01-23 | SAGE | Sale | 7,500 | 134.81 | 1,011,075 |
| 2018-05-08 | SAGE | Sale | 7,000 | 154.00 | 1,078,000 |
| 2018-05-08 | SAGE | Option Ex | 7,000 | 8.92 | 62,440 |
Table 2. Insider trading of Alkermes Plc. (ALKS) by Frates James M
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-05-14 | ALKS | Option Ex | 21,983 | 11.74 | 258,080 |
| 2020-03-01 | ALKS | Option Ex | 4,500 | .00 | 0 |
| 2020-02-21 | ALKS | Option Ex | 5,825 | .00 | 0 |
| 2019-09-13 | ALKS | Option Ex | 20,000 | 11.74 | 234,800 |
| 2019-03-01 | ALKS | Option Ex | 4,500 | .00 | 0 |
| 2019-02-26 | ALKS | Option Ex | 2,625 | .00 | 0 |
| 2019-02-17 | ALKS | Option Ex | 3,000 | .00 | 0 |
| 2019-02-16 | ALKS | Option Ex | 3,375 | .00 | 0 |
| 2018-06-12 | ALKS | Sale | 16,842 | 50.01 | 842,184 |
| 2018-03-01 | ALKS | Option Ex | 4,500 | .00 | 0 |
| 2018-03-03 | ALKS | Option Ex | 2,813 | .00 | 0 |
| 2018-02-26 | ALKS | Option Ex | 2,625 | .00 | 0 |
| 2017-11-29 | ALKS | Option Ex | 20,932 | 12.29 | 257,254 |
| 2017-11-29 | ALKS | Sale | 20,932 | 50.87 | 1,064,852 |
| 2017-11-08 | ALKS | Option Ex | 20,932 | 12.29 | 257,254 |
| 2017-11-08 | ALKS | Sale | 20,932 | 47.58 | 996,007 |
| 2017-05-28 | ALKS | Option Ex | 2,500 | .00 | 0 |
| 2017-03-03 | ALKS | Option Ex | 2,812 | .00 | 0 |
| 2017-03-01 | ALKS | Option Ex | 4,500 | .00 | 0 |
| 2017-02-26 | ALKS | Option Ex | 2,625 | .00 | 0 |
| 2016-12-14 | ALKS | Sale | 25,000 | 54.96 | 1,374,050 |
| 2016-12-14 | ALKS | Option Ex | 25,000 | 12.94 | 323,375 |
| 2016-12-07 | ALKS | Option Ex | 23,731 | 13.85 | 328,555 |
| 2016-12-07 | ALKS | Sale | 23,731 | 56.43 | 1,339,211 |
| 2016-11-18 | ALKS | Option Ex | 6,042 | 16.55 | 99,995 |
| 2016-10-05 | ALKS | Option Ex | 5,000 | .00 | 0 |
| 2016-05-28 | ALKS | Option Ex | 2,500 | .00 | 0 |
| 2016-05-21 | ALKS | Option Ex | 3,750 | .00 | 0 |
| 2015-11-24 | ALKS | Option Ex | 5,523 | 18.11 | 99,993 |
| 2015-11-10 | ALKS | Option Ex | 10,000 | 15.95 | 159,500 |
| 2015-11-10 | ALKS | Sale | 10,000 | 72.34 | 723,400 |
| 2015-10-13 | ALKS | Option Ex | 20,000 | 13.06 | 261,200 |
| 2015-10-13 | ALKS | Sale | 20,000 | 60.00 | 1,200,080 |
| 2015-09-15 | ALKS | Sale | 20,000 | 71.12 | 1,422,400 |
| 2015-09-15 | ALKS | Option Ex | 20,000 | 13.06 | 261,200 |
| 2015-08-11 | ALKS | Sale | 10,000 | 67.88 | 678,790 |
| 2015-08-11 | ALKS | Option Ex | 10,000 | 14.38 | 143,800 |
| 2015-07-14 | ALKS | Option Ex | 20,000 | 13.06 | 261,200 |
| 2015-07-14 | ALKS | Sale | 20,000 | 65.87 | 1,317,360 |
| 2015-06-16 | ALKS | Option Ex | 10,000 | 11.74 | 117,400 |
| 2015-06-16 | ALKS | Sale | 10,000 | 58.63 | 586,350 |
| 2015-05-28 | ALKS | Option Ex | 2,500 | .00 | 0 |
| 2015-05-20 | ALKS | Option Ex | 3,750 | .00 | 0 |
| 2015-05-21 | ALKS | Option Ex | 3,750 | .00 | 0 |
| 2015-05-12 | ALKS | Sale | 10,000 | 59.34 | 593,420 |
| 2015-05-12 | ALKS | Option Ex | 10,000 | 11.74 | 117,400 |
| 2015-04-15 | ALKS | Option Ex | 10,000 | 9.21 | 92,100 |
| 2015-04-15 | ALKS | Sale | 10,000 | 62.42 | 624,220 |
| 2015-03-10 | ALKS | Option Ex | 10,000 | 9.21 | 92,100 |
| 2015-03-10 | ALKS | Sale | 10,000 | 66.51 | 665,100 |
| 2015-03-03 | ALKS | Option Ex | 2,812 | .00 | 0 |
| 2015-02-03 | ALKS | Sale | 10,000 | 71.44 | 714,389 |
| 2015-02-03 | ALKS | Option Ex | 10,000 | 9.21 | 92,100 |
| 2015-01-15 | ALKS | Option Ex | 10,000 | 9.21 | 92,100 |
| 2015-01-15 | ALKS | Sale | 10,000 | 67.28 | 672,800 |
Table 3. Insider trading of Amylyx Pharmaceuticals, Inc. (AMLX) by Frates James M
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-09-30 | AMLX | Sale | 10,558 | 14.65 | 154,653 |
| 2025-03-31 | AMLX | Sale | 10,896 | 3.47 | 37,809 |
| 2024-09-12 | AMLX | Buy | 40,000 | 2.53 | 101,359 |
| 2024-03-05 | AMLX | Sale | 1,792 | 18.73 | 33,560 |
| 2024-01-09 | AMLX | Sale | 2,716 | 16.33 | 44,346 |
| 2023-08-23 | AMLX | Option Ex | 18,165 | 6.88 | 124,975 |
| 2023-05-16 | AMLX | Option Ex | 32,500 | 6.88 | 223,600 |
| 2023-05-16 | AMLX | Sale | 32,500 | 27.26 | 886,047 |
| 2023-03-16 | AMLX | Sale | 32,500 | 32.16 | 1,045,265 |
| 2023-01-06 | AMLX | Sale | 2,658 | 36.43 | 96,841 |
| 2022-12-30 | AMLX | Option Ex | 5,000 | 6.88 | 34,400 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Frates James M
(Chief Financial Officer of Amylyx Pharmaceuticals, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.